Last reviewed · How we verify
Experimental vaccine 3
At a glance
| Generic name | Experimental vaccine 3 |
|---|---|
| Sponsor | Sinovac Research and Development Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (PHASE1)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) (PHASE1)
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above (PHASE3)
- Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (PHASE2)
- GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental vaccine 3 CI brief — competitive landscape report
- Experimental vaccine 3 updates RSS · CI watch RSS
- Sinovac Research and Development Co., Ltd. portfolio CI